Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Organisation › Details

MolMed S.p.A. (MLMD.MI)

MolMed S.p.A. is a medical biotechnology company focused on research, development, clinical validation and manufacturing of novel cell and gene therapies. MolMed’s pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immunosuppression prophylaxis, currently in Phase III in high risk leukaemias and recommended by CHMP for Conditional Marketing Authorization; NGR-hTNF is a novel therapeutic agent for solid tumours exerting antitumor activity through its specific binding to blood vessels that feed the tumour mass, currently investigated in a broad clinical programme; CAR-CD44v6, an immunogene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from discovery to market, including scale-up and cGMP production of market-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and a local unit at OpenZone in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI). *


Products Industry gene therapy
  Industry 2 biopharmaceutical
  Street 58 via Olgettina
  City 20132 Milan
  Tel +39-02-21277-1
    Address record changed: 2013-05-16
Basic data Employees n. a.
    * Document for �About Section�: MolMed S.p.A.. (6/24/16). "Press Release: MolMed Receives Positive CHMP Opinion Recommending Conditional Marketing Authorisation for Zalmoxis". Milan.
Record changed: 2018-12-04


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for MolMed S.p.A. (MLMD.MI)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

» top